Morgan Stanley Remains Bullish on Intuitive Surgical (ISRG)

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best medical stocks to buy now. Morgan Stanley analyst Patrick Wood maintained a Buy rating on Intuitive Surgical, Inc. (NASDAQ:ISRG) on September 29 and set a price target of $650.00.

The analyst based the optimistic rating on the company’s potential in the endoluminal robotics market, reasoning that the recent success of EndoQuest’s PARADIGM trial reflects a notable opportunity for Intuitive Surgical, Inc. (NASDAQ:ISRG). The PARADIGM trial demonstrated the feasibility of performing complex colorectal lesions using endoscopic submucosal dissection (ESD).

Wood noted that while the procedure is technically challenging, it offers improved clinical outcomes compared to the more common methods in practice in the United States, which is why its success could pave the way for a broader adoption of robotic-assisted surgeries.

Intuitive Surgical, Inc. (NASDAQ:ISRG) has an elaborate ecosystem of services and products that provide robotic-assisted surgical solutions and invasive care. Its products include the Ion Endoluminal and the Da Vinci Surgical systems.

While we acknowledge the potential of ISRG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.